Guardant Health, Inc. (GH): Results of Operations and Financial Condition
Guardant Health, Inc. (GH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to
How this was made
The 30-second read
Why it matters
The filing provides fresh, decision-relevant numbers: Q2 revenue growth, updated full-year revenue and segment growth assumptions, margin outlook, and free cash flow burn range, plus new FDA approvals and Shield coverage/guideline inclusion that can drive incremental demand.
Market read
A same-day 8-K with raised guidance and multiple adoption catalysts typically drives repricing of growth and adoption curves for liquid biopsy and screening franchises.
What to watch
Traders may scrutinize whether the higher Shield volume and lab capacity investments compress margins or extend cash burn beyond the updated $195M to $205M outlook.
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Revenue increased 44%, led by Oncology growth and Screening growth of over 250%, while the company raised full-year 2026 revenue guidance. Losses and free cash flow burn increased year over year as Guardant expanded commercial infrastructure, marketing activities and laboratory capacity.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $335.0 million | – | 44% |
| Oncology revenueGAAP | $219.1 million | – | 38% |
| Biopharma & Data revenueGAAP | $60.9 million | – | 9% |
| Screening revenueGAAP | $52.9 million | – | over 250% |
| Licensing and other revenueGAAP | $2.1 million | – | – |
| Oncology test volumeother | approximately 104,000 oncology tests | – | 63% |
| Shield screening test volumeother | approximately 66,000 Shield™ screening tests | – | – |
| Gross profitGAAP | $219.0 million | – | 45% |
| Gross marginGAAP | 65% | – | – |
| Non-GAAP gross profitnon-GAAP | $223.1 million | – | 45% |
| Non-GAAP gross marginnon-GAAP | 67% | – | – |
| Operating expensesGAAP | $348.1 million | – | – |
| Non-GAAP operating expensesnon-GAAP | $288.3 million | – | – |
| Net lossGAAP | $120.1 million | – | – |
| Net loss per shareGAAP | $0.90 | – | – |
| Non-GAAP net lossnon-GAAP | $56.2 million | – | – |
| Non-GAAP net loss per sharenon-GAAP | $0.42 | – | – |
| Adjusted EBITDA lossnon-GAAP | $55.9 million | – | – |
| Free cash flownon-GAAP | $(69.5) million | – | – |
| Cash, cash equivalents, and restricted cashother | $1.2 billion | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| OncologyDriven primarily by an increase in Oncology test volume, which grew 63% over the prior year period. | $219.1 million | – | 38% |
| Biopharma & DataNo specific driver was reported. | $60.9 million | – | 9% |
| ScreeningDriven primarily by an increase in Shield screening test volume, which grew to approximately 66,000 tests. | $52.9 million | – | over 250% |
| Licensing and otherNo specific driver was reported. | $2.1 million | – | – |
full year 2026 outlook
- Revenue$1.34 to $1.36 billion, representing growth of 36% to 38% compared to full year 2025
- Gross marginnon-GAAP gross margin to be in the range of 64% to 65%
- Operating expensestotal non-GAAP operating expenses to be in the range of $1.08 to $1.10 billion
- NoteOncology revenue is now expected to grow approximately 30% in 2026.
- NoteOncology volume is now expected to grow to approximately 50% in 2026.
- NoteBiopharma & Data revenue growth is expected to be in the low double-digit range.
- NoteScreening revenue is now expected to be in the range of $218 to $230 million.
- NoteShield volume of 270,000 to 285,000 tests.
- Notefull-year free cash flow burn of $195 million to $205 million.
What drove it
- Oncology revenue growth was driven primarily by Oncology test volume, which grew 63% over the prior year period.
- Screening revenue growth was driven primarily by Shield screening test volume, which grew to approximately 66,000 tests from approximately 16,000 tests in the prior year period.
- The company cited commercial infrastructure expansion and marketing activities to support Shield and Oncology growth as the primary reasons for higher operating expenses.
- Guardant received FDA approval for Guardant360® Liquid CDx and for a higher-throughput, lower-COGS Shield workflow.
- Shield was included in updated American Cancer Society colorectal cancer screening guidelines and obtained coverage from UnitedHealth Group.
Concerns
- Net loss was $120.1 million, compared to $99.9 million for the corresponding prior year period.
- Adjusted EBITDA loss was $55.9 million, compared to a $51.9 million loss for the corresponding prior year period.
- Free cash flow was $(69.5) million, compared to $(65.9) million for the corresponding prior year period.
- Full-year free cash flow burn is expected to be $195 million to $205 million as Guardant accelerates investment in laboratory capacity.
- Biopharma & Data revenue grew 9%, below the reported growth rates for Oncology and Screening.
What to watch
- Oncology revenue is expected to grow approximately 30% in 2026 and Oncology volume is expected to grow to approximately 50%.
- Screening revenue is expected to be $218 to $230 million, driven by Shield volume of 270,000 to 285,000 tests.
- Biopharma & Data revenue growth is expected to be in the low double-digit range.
- Full-year 2026 non-GAAP gross margin is expected to be 64% to 65%.
- Total non-GAAP operating expenses are expected to be $1.08 to $1.10 billion and full-year free cash flow burn is expected to be $195 million to $205 million.
Balance sheet and cash flow
- Free cash flow for the second quarter of 2026 was $(69.5) million, as compared to $(65.9) million for the corresponding prior year period.
- Cash, cash equivalents, and restricted cash were $1.2 billion as of June 30, 2026.
- The revised full-year free cash flow burn range reflects accelerated investment in laboratory capacity to support rapid Shield volume growth and represents an improvement from the $233 million of free cash flow burn reported for full-year 2025.
Analysis
Guardant reported $335.0 million of second-quarter 2026 revenue, up 44% from $232.1 million in the corresponding prior-year period. Growth was broad based, with Oncology revenue up 38% to $219.1 million, Screening revenue up over 250% to $52.9 million, and Biopharma & Data revenue up 9% to $60.9 million. Oncology test volume grew 63% to approximately 104,000 oncology tests, while Shield screening test volume reached approximately 66,000 tests, compared with approximately 16,000 tests in the prior-year period.
Screening was the fastest-growing reported revenue line and was supported by several operating milestones. The company cited Shield's inclusion in updated American Cancer Society colorectal cancer screening guidelines, UnitedHealth Group coverage, and FDA approval for a higher-throughput, lower-COGS Shield workflow. Oncology momentum was accompanied by FDA approval for Guardant360® Liquid CDx, as well as companion-diagnostic approval for Guardant360® CDx in HER2 (ERBB2)-mutant advanced non-small cell lung cancer.
Reported gross profit increased 45% to $219.0 million and GAAP gross margin was 65%, unchanged from the prior-year period. Non-GAAP gross profit increased 45% to $223.1 million, while non-GAAP gross margin rose to 67% from 66%. Higher spending accompanied the growth investment: GAAP operating expenses were $348.1 million versus $257.3 million, and non-GAAP operating expenses were $288.3 million versus $215.3 million. The company attributed the increases primarily to commercial infrastructure expansion and marketing activities for Shield and Oncology, with GAAP expense also affected by increased stock-based compensation.
Profitability and cash use remain central areas of focus. GAAP net loss increased to $120.1 million from $99.9 million, adjusted EBITDA loss increased to $55.9 million from a $51.9 million loss, and free cash flow was $(69.5) million versus $(65.9) million. Cash, cash equivalents, and restricted cash were $1.2 billion as of June 30, 2026.
Management raised full-year 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%, and increased expected Oncology growth, Oncology volume growth, Screening revenue, and Shield volume. It maintained expected non-GAAP gross margin of 64% to 65%, while raising non-GAAP operating expense guidance to $1.08 to $1.10 billion and increasing expected free cash flow burn to $195 million to $205 million. The revised cash-flow outlook reflects accelerated laboratory-capacity investment to support rapid Shield volume growth.
Management, verbatim
Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year.
Helmy Eltoukhy, co-founder and co-CEO
The inclusion of the Shield blood test in the American Cancer Society’s screening guidelines, together with UnitedHealth Group’s broad coverage decision, represents powerful validation of Shield’s clinical utility and its potential to improve access to screening.
AmirAli Talasaz, co-founder and co-CEO
Not in the filing
stated, not guessed- Previous-release outlook was not provided, so actual performance versus prior guidance is not assessed.
- Quarterly prior-quarter revenue, segment revenue, gross profit, gross margin, operating expenses, net loss, EPS, adjusted EBITDA loss, free cash flow, and test-volume comparisons were not reported.
- GAAP operating income or loss was not reported.
- GAAP and non-GAAP tax rate were not reported.
- Operating cash flow and purchases of property and equipment were not separately reported.
- Debt balance was not reported.
- Share repurchases, dividends, and other capital returns were not reported.
- Diluted share count was not reported.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8-K Item 2.02 reporting Guardant Health’s Q2 2026 financial results and updated 2026 guidance, alongside FDA and commercial adoption milestones.
Ticker impact
Guardant reported Q2 2026 revenue of $335.0M (+44% YoY) and raised 2026 revenue guidance to $1.34 to $1.36B (+36% to 38%).
Near-term bias higher as traders price the raised 2026 revenue and Shield volume outlook; follow-through depends on whether margins and cash burn trajectory stabilizes.
Guidance midpoint rises versus prior range, Shield test volume guidance is increased, and the filing includes fresh FDA approvals and insurer coverage, all of which are direct demand and adoption drivers.
Market effects
Supports sentiment for precision oncology and liquid biopsy adoption, especially colorectal screening and companion diagnostic expansion.
Primarily US-focused adoption signals (FDA approvals, US insurer coverage, ACS guideline inclusion) may influence US biotech tape.
Companion diagnostic approval tied to a specific therapy can strengthen global commercial confidence, though the filing is US-centric.
Counterpoint
Despite revenue growth, the company still reports large net losses and free cash flow burn, and operating expenses are rising faster than revenue.
Key entities
- companyGuardant Health, Inc.
Precision oncology company reporting Q2 2026 results and raising 2026 revenue guidance; highlights FDA approvals and Shield screening adoption.
- regulatorU.S. Food and Drug Administration (FDA)
Approved Guardant360 Liquid CDx and Guardant360 CDx as a companion diagnostic for HERNEXEOS (HER2-mutant advanced NSCLC).
- commercial_partnerUnitedHealth Group
Provided Shield coverage, described as the first major commercial insurer to cover the test.
- guideline_bodyAmerican Cancer Society (ACS)
Updated colorectal cancer screening guidelines to include Shield.
- partnerBoehringer Ingelheim
HERNEXEOS is referenced as the therapy for which Guardant360 CDx is approved as a companion diagnostic.
